Retatrutide is a triple agonist (GLP-1 + GIP + glucagon); tirzepatide is a dual agonist (GLP-1 + GIP). Retatrutide has the larger weight-loss effect in published research; tirzepatide has the larger body of comparative data.
Side-by-side comparison
| Property | Retatrutide | Tirzepatide |
|---|---|---|
| Targets | GLP-1, GIP, glucagon | GLP-1, GIP |
| Class | Triple agonist | Dual agonist |
| Half-life (research) | ~6 days | ~5 days |
| Sequence length | 39 aa | 39 aa |
| Albumin binding | C20 fatty-diacid | C20 fatty-diacid |
| Research stage (May 2026) | Phase III ongoing | Approved |
| Comparative weight effect | Larger | Smaller |
When researchers choose Retatrutide
Retatrutide is typically selected when the research question targets its specific mechanism or when comparative data against Tirzepatide is the goal. ISO 17025 batch certificates are included with every shipment.
When researchers choose Tirzepatide
Tirzepatide is typically selected when the research question targets its specific mechanism. Both compounds undergo the same HPLC and mass-spec verification.
Reconstitution and dosing
Both peptides reconstitute identically with bacteriostatic water. See the reconstitution guide for sterile technique and the dosage guide for concentration maths.
FAQ: Retatrutide vs Tirzepatide
Which is stronger in weight-loss research?
In published research to date, retatrutide has produced the larger average weight reduction. This is attributed to its added glucagon-receptor activity.
Is retatrutide just tirzepatide plus a glucagon agonist?
Conceptually similar but mechanistically distinct — retatrutide is a separate molecule designed for balanced triple-agonist activity.
Can the two be compared head-to-head?
Yes, many research designs include both, often with semaglutide as a third comparator. Always design and review studies according to your institutional protocols.